This study aimed to determine the impact of Pentoxifylline on inflammatory biomarkers and the progression of chronic kidney disease in non-diabetic patients.
Chronic kidney disease (CKD) is a progressive condition that affects \>10% of the general population worldwide, amounting to \>800 million individuals. The diagnosis of CKD is established by laboratory testing, most often by estimating glomerular filtration rate (GFR) from a filtration marker, such as serum creatinine or cystatin C, using various formulas, or by testing urine for albumin or protein (or both). Pentoxifylline (PTX), a synthetic dimethylxanthine derivative used initially to treat intermittent claudication in patients with peripheral arterial disease due to its hemorheological effects, has been shown to have potent antioxidant, anti-inflammatory, antidiabetic, anti-cellular-damage, and antifibrotic effects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
42
Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.
Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.
Ain Shams University
Cairo, Egypt
Levels of inflammatory marker
Levels of inflammatory marker was recorded.
Time frame: 3 months post-procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.